Ailani Myers Accelerating Innovation in Medicine to Cure Kids with Cancer Act
Sponsored By: Representative McCaul, Michael T. [R-TX-10]
Introduced
Summary
Would create a federal, data- and AI-driven program to accelerate pediatric cancer diagnosis, treatment, and cures. It would set up an interagency Coordinator of AI Innovation and a Childhood Cancer Data Initiative to standardize, link, and share pediatric cancer data for research and care.
Show full summary
- Families and patients: Would collect and link clinical, molecular, and imaging data for children, adolescents, and young adults to improve diagnosis, personalize treatment, and track survivorship and quality of life.
- Researchers and clinicians: Would fund and build AI-ready data platforms, standards, and tools, including a CCDI Data Ecosystem and support for NCI‑designated cancer center projects to speed biomarker discovery and trial design.
- Federal agencies and health IT: Would align HHS components (NIH, FDA, CMS, ARPA‑H, ONC) and other agencies (DOD, DOE, VA, NSF, NIST, OSTP) on data sharing, privacy-compliant interoperability standards, and pediatric-focused AI guidance.
*Would authorize new federal spending, including $100 million per year for FY2027–FY2031 for the Childhood Cancer Data Initiative. If appropriated, this would increase federal outlays.*
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
AI for pediatric cancer research and trials
If enacted, the NCI Director would fund and expand use of artificial intelligence to predict patient response, progression, and toxicity and to find diagnostic and prognostic biomarkers. The NCI would make CCDI data systems AI‑ready and harmonize multisource data for AI analysis. The Secretary would also be required to support using multimodal data and AI to improve pediatric cancer clinical trial design, recruitment, conduct, and interpretation.
Child health data standards and privacy
If enacted, HHS through the ONC would develop interoperability standards for patient data to be used with AI and finalize them within two years. The standards must cover structured and unstructured data, allow privacy‑compliant exchanges, and prioritize pediatric patients. All activities under the bill would have to follow applicable Federal and State privacy laws, including HIPAA rules.
New childhood cancer data program
If enacted, the bill would create a Childhood Cancer Data Initiative run by NCI to collect and share data on people diagnosed as children, teens, or young adults. The program would fund molecular testing, non‑invasive technologies, AI‑ready data platforms, and a National Childhood Cancer Registry. The Secretary would name a CCDI Director on the NCI Director's recommendation. Congress would be asked to appropriate $100,000,000 for each of fiscal years 2027 through 2031 to carry out CCDI activities.
New federal pediatric cancer coordinator
If enacted, the bill would create a federal Coordinator to align agencies and partners on pediatric cancer data, research, and AI activities. The Coordinator would work across HHS, DOD, DOE, VA, NSF, NIST, OSTP and others and consult with the NCI Director. The President would also designate an officer or office to coordinate AI efforts and must notify the appropriate congressional committees within 30 days of that designation.
Funding and oversight reporting rules
If enacted, the bill would authorize 'such sums as may be necessary' for non‑CCDI sections for fiscal years 2027 through 2031. The Secretary would have to send an interim report to Congress within 180 days and then annual reports starting within one year and continuing through fiscal year 2031. Reports would detail activities, spending, progress on data sharing and privacy, barriers, and measures of pediatric cancer outcomes.
Sponsors & CoSponsors
Sponsor
McCaul, Michael T. [R-TX-10]
TX • R
Cosponsors
Rep. Bera, Ami [D-CA-6]
CA • D
Sponsored 9/14/2026
Rep. Kelly, Mike [R-PA-16]
PA • R
Sponsored 9/14/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov